Anti-VEGF agents: As appealing targets in the setting of COVID-19 treatment in critically ill patients
A Sahebnasagh, SM Nabavi, HRK Kashani… - International …, 2021 - Elsevier
Recently, the medications used for the severe form of the coronavirus disease-19 (COVID-
19) therapy are of particular interest. In this sense, it has been supposed that anti-VEGF …
19) therapy are of particular interest. In this sense, it has been supposed that anti-VEGF …
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
The novel coronavirus pandemic has emerged as one of the significant medical-health
challenges of the current century. The World Health Organization has named this new virus …
challenges of the current century. The World Health Organization has named this new virus …
Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19–A theoretical perspective
A Yaqinuddin, AR Ambia, TA Elgazzar… - Medical …, 2021 - Elsevier
COVID-19 is an airway disease that has affected~ 125 million people worldwide, caused by
a novel coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) …
a novel coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) …
Targeting the immune system for pulmonary inflammation and cardiovascular complications in COVID-19 patients
S Colafrancesco, R Scrivo, C Barbati, F Conti… - Frontiers in …, 2020 - frontiersin.org
In December 2019, following a cluster of pneumonia cases in China caused by a novel
coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons
The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)
responsible for coronavirus disease 2019 (COVID-19) has developed into an …
responsible for coronavirus disease 2019 (COVID-19) has developed into an …
[HTML][HTML] Role of monoclonal antibody drugs in the treatment of COVID-19
C Ucciferri, J Vecchiet, K Falasca - World journal of clinical cases, 2020 - ncbi.nlm.nih.gov
Currently clinicians all around the world are experiencing a pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this …
Targeting inflammation and cytokine storm in COVID-19
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million …
Immunosuppressant therapies in COVID-19: is the TNF axis an alternative?
Y Palacios, L Chavez-Galan - Pharmaceuticals, 2022 - mdpi.com
The study of cytokine storm in COVID-19 has been having different edges in accordance
with the knowledge of the disease. Various cytokines have been the focus, especially to …
with the knowledge of the disease. Various cytokines have been the focus, especially to …
Cytokine storm in COVID-19: Potential therapeutics for immunomodulation
MM Rana - Journal of Research in Clinical Medicine, 2020 - library.2pressrelease.co.in
The outbreak of new coronavirus disease-20119 or COVID-19 infection has become a
global health emergency at the beginning of this year. Currently, no specific vaccines and …
global health emergency at the beginning of this year. Currently, no specific vaccines and …
Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19
J Geng, F Wang, Z Huang, X Chen, Y Wang - Cytokine, 2021 - Elsevier
The overproduction of proinflammatory cytokines, resulting in what has been described as a
cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology …
cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology …